

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

APOTEX INC.,
Petitioner

v.

NOVO NORDISK A/S,
PATENT OWNER

CASE IPR2024-00631
U.S. PATENT NO. 10,335,462
ISSUED: JULY 2, 2019

TITLE:
USE OF LONG-ACTING GLP-1 PEPTIDES

**APOTEX'S REPLY TO PATENT OWNER'S OPPOSITION TO
PETITIONER'S MOTION FOR JOINDER**

PROTECTIVE ORDER MATERIAL

PROTECTIVE ORDER MATERIAL

Apotex replies to Novo's opposition to Apotex's motion for joinder or alternatively, consolidation. *See* Paper Nos. 5, 9. As for joinder, Novo principally contends that Apotex failed to show good cause for its motion and improperly waited to file it. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] And Novo has shown no strategic advantage or improper purpose relating to the timing of Apotex's filings, because, quite simply, there was none. As for consolidation, Novo oddly asserts that scheduling issues preclude merging this proceeding with Mylan's, even though Apotex will serve as an understudy and follow the Mylan proceeding's schedule. Overall, Novo has not disputed that joinder or consolidation would promote efficient resolution of the cases or identified any prejudice resulting from either approach. The Board should thus grant Apotex's motion.

NOVO DOES NOT DISPUTE THAT *KYOCERA* FAVORS JOINDER

To begin, Novo does *not* dispute that the following *Kyocera* factors favor joinder: Apotex's petition presents no new unpatentability grounds, joinder will not impact the lead case's schedule, and briefing and discovery may be simplified.

PROTECTIVE ORDER MATERIAL

Mot. 6-9. Novo even acknowledges that Apotex agreed to essentially the same conditions that resolved Novo’s opposition to DRL’s and Sun’s motions for joinder to the Mylan proceeding. Opp. 7-9 n.5. Moreover, Novo has identified *no* prejudice that would result from joinder. In sum, the fact that these factors undisputedly favor Apotex, coupled with the absence of prejudice, compel joinder.

THE BOARD SHOULD WAIVE THE JOINDER TIMING REQUIREMENT

Novo argues that Petitioner has not shown “special” circumstances to justify waiving the joinder deadline. Opp. 1-3. But Apotex has shown exactly such circumstances. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

¹ [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

² In light of these efforts, Novo’s assertion that preparing a copycat petition “required no substantive work” is unfounded. Opp. 5-6.

³ The “waiting” cases Novo cites are off point. In *Roche*, petitioner relied upon an acquisition to explain its delay despite filing its joinder motion over 4 months after publicly announcing the acquisition. *Roche*, IPR2015-01091, Paper No. 18, at 10-11. In *Shaw*, petitioner strategically waited for a Board rehearing decision prior to filing its motion. *Shaw*, IPR2013-00584, Paper No. 20, at 4-5.

PROTECTIVE ORDER MATERIAL

[REDACTED]

[REDACTED]

[REDACTED]⁴

Novo attempts to distinguish *GlobalFoundries* and *Sony*, cases in which the Board waived the filing deadline, on the basis that the petitioners in those cases attempted to join the earlier IPR proceeding within the filing deadline. Opp. 6-7.

[REDACTED]

[REDACTED]. And critically,

Novo ignores the key similarities between those cases and this one, *viz.*, that the petitions raised no new unpatentability grounds, the trial schedule did not need to be adjusted, and the petitioners agreed to serve as silent understudies. *Id.* at 10.

As a throwaway, Novo asserts that Apotex's motion was unauthorized. Opp. 1 n.1, 9. But seeking authorization was unnecessary, because Apotex filed its motion with its petition. *See* Trial Practice Guidelines at 37 (providing that prior

⁴ [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.